MSB (ASX) Let me clarify

Originally posted by Kakala: ↑

The amount of crap that is spoken on HotCopper is mind blowing. Let me clarify!

As per my discussion with Cardiologist - I'll do my best some of it was very technical:

1. The primary end point of temporary weaning (taking them of the heart pump for a little while) was not achieved, overall, because pump thrombosis reduced the number of wean attempts. NOTHING TO DO WITH MSB CELLS!!!!. NOTE this was NIH continuation of the original end point, not FDA's focus!

2. FDA focus was on GI Bleeding, why because reduction in bleeding results in reduction in hospitalisation and as a consequence significant reduction on cost. And as is stipulated in the announcement this is what the FDA is focused on.

"Under the RMAT designation, Mesoblast received specific guidance from the FDA that reduction in major GI bleeding episodes and related hospitalizations in the current trial is a clinically meaningful outcome with a high unmet need that could meet requirements for an approvable regulatory endpoint. In contrast, the FDA advised that the primary endpoint in the current trial of temporary weaning from full LVAD support is considered a biomarker and is not a clinically meaningful outcome in and of itself."

3. This trial v Phase CHF are very different trials, LVAD trial does not give any insight into potential results of Phase 3 CHF. This trial was focussed on reduction in bleeding for the FDA. Phase 3 end points is reduction in Hospitalisation and Mortality rates

Expand

Very good points , can any one explain why trading restarted when it did? MSB should have been placed in a TH till tomorrow after the conference call tonight.
ASX should not have opened trade.
Did MSB request a TH?. Did MSB request trading to restart? Or did ASX restart trading without approval from MSB.

Something wrong has happened

Originally posted by angelus512: ↑

Thanks Kakala. Good to see you still around. Helps put it all into perspective. Today we have seen a clear disconnect between exepctations and reality. I've no idea what the price will do in the coming days but this will (somewhat) shake out in the wash of what remains of the year.

The next question is what do we have to look forward to next on the calendar? A partnership could come at any time so I don't mean that. I mean trial result timelines of whats next and any market approval access upcoming soon?

I have a feeling we are waiting on some Disc results soon?

Expand

No.	Vol.	Price($)
1	23545	$1.05

No.

Vol.

Price($)

23545

$1.05

Price($)	Vol.	No.
$1.05	339479	5

Price($)

Vol.

No.

$1.05

339479

No.	Vol.	Price($)
1	23545	1.045
1	10000	1.040
8	181213	1.035
15	391706	1.030
1	15570	1.025

No.

Vol.

Price($)

23545

1.045

10000

1.040

181213

1.035

391706

1.030

15570

1.025

Price($)	Vol.	No.
1.050	339479	5
1.055	21365	3
1.060	376981	13
1.065	55888	5
1.070	93334	6

Price($)

Vol.

No.

1.050

339479

1.055

21365

1.060

376981

1.065

55888

1.070

93334

(20min delay)
Last $1.05		Change 0.080(8.25%)		Mkt cap ! $1.198B

Open	High	Low	Value	Volume
99.5¢	$1.06	99.0¢	$4.930M	4.779M

Latitude 66 Shares Surge 8900% on Promising Exploration Update

Alkane Resources hit 57.2Kozpa gold production through FY24 – and eyeing 70Ktpa in FY26

XReality Group wins $800K contract from Aus Government for military and police VR training tech

ACCC raises competition concerns about acquisition of Lendlease projects

Askari sets exploration target of up to 323K ounces Au at Burracoppin

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Top Stories

Latitude 66 Shares Surge 8900% on Promising Exploration Update

Alkane Resources hit 57.2Kozpa gold production through FY24 – and eyeing 70Ktpa in FY26

XReality Group wins $800K contract from Aus Government for military and police VR training tech

ACCC raises competition concerns about acquisition of Lendlease projects

Askari sets exploration target of up to 323K ounces Au at Burracoppin

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News